Zimmer Biomet (ZBH) fundamentals: P/E, valuation, undervalued?
Zimmer Biomet · Health Care · ref. ETF XLV · price $92.08
In short — Zimmer Biomet trades at 22.3× earnings (P/E), 10.2× forward, with a net margin of 9.5 % and revenue growth of +5 %. Read: Cheap for the growth (P/E 10 for ~34% growth (PEG 0.3)).
Is Zimmer Biomet stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$92.08-6.4% over range
Oct 14, 25low $79.58 · high $103.98Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
33% recommend buying · 12 analysts
Valuation : Cheap for the growth — P/E 10 for ~34% growth (PEG 0.3)
Valuation
22.3
P/E (price/earnings)
10.2
Forward P/E
0.66
PEG
1.4
Price/book (P/B)
$17.6B
Market cap
4.12
EPS
Profitability & growth
9.5 %
Net margin
+5 %
Revenue growth
+34 %
Earnings growth
$7.6B
Total debt
Zimmer Biomet income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $6.9B | $231M | 3.3 % |
| 2023 | $7.4B | $1.0B | 13.8 % |
| 2024 | $7.7B | $904M | 11.8 % |
| 2025 | $8.2B | $705M | 8.6 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Zimmer Biomet's P/E and is the stock undervalued? What's a good P/E?
Zimmer Biomet's P/E is 22.3 (forward 10.2). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is Zimmer Biomet profitable?
Zimmer Biomet has a net margin of 9.5 % (EPS 4.12). The company is profitable.
Is ZBH stock expensive?
Our read: "Cheap for the growth" — P/E 10 for ~34% growth (PEG 0.3). Cross-check with growth and sector.
💬 A question about Zimmer Biomet? The JPI assistant answers using our backtest data.
Keep exploring Zimmer Biomet